Ali Shamseddine
Overview
Explore the profile of Ali Shamseddine including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
192
Citations
2179
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abbas N, Chehade L, Tarhini H, Abdul Sater Z, Shamseddine A
Int J Environ Res Public Health
. 2025 Feb;
22(2).
PMID: 40003490
Colorectal cancer (CRC) is a significant public health concern, ranking third in incidence and second in mortality worldwide. Despite rising CRC incidence rates in the Arab world, understanding of trends...
2.
Temraz S, Charafeddine M, Khalifeh M, Shamseddine A
J Epidemiol Glob Health
. 2025 Feb;
15(1):28.
PMID: 39961967
Purpose: Pancreatic cancer remains a deadly disease with a low survival rate specifically if diagnosed at later stages. Surgery is one of the mainstay treatments for early stage disease but...
3.
Balancing anticancer therapy efficacy and safety in advanced hepatocellular carcinoma: a case report
Mourad M, Al Mahmasani L, Abbas N, Sainamthip P, Freile B, Zayed A, et al.
J Gastrointest Oncol
. 2025 Jan;
15(6):2712-2720.
PMID: 39816020
Background: Hepatocellular carcinoma (HCC) is a significant health problem associated with several risk factors, increasingly driven by non-alcoholic steatohepatitis and metabolic syndrome. This association poses a challenge for the primary...
4.
Abbas N, Zahreddine L, Tawil A, Natout M, Shamseddine A
Diagnostics (Basel)
. 2024 Nov;
14(22).
PMID: 39594178
: Pancreatic cancer is among the malignancies with the poorest prognosis, largely due to its aggressive nature and resistance to conventional therapies. : This report describes the case of a...
5.
Pereira M, Couto E, Shamseddine A, Macedo T
Cureus
. 2024 Nov;
16(10):e71299.
PMID: 39529789
Gastrointestinal stromal tumors (GISTs) are rare malignant tumors that arise from the connective tissues of the gastrointestinal tract. Reports about GISTs treated with imatinib for over five years are exceedingly...
6.
Chehade L, Dagher K, Shamseddine A
Cancer Treat Res Commun
. 2024 Oct;
41:100847.
PMID: 39418850
The management of locally advanced rectal cancer (LARC) requires personalized treatment to improve outcomes and maintain quality of life. This narrative review examines the recent developments in management, focusing on...
7.
Abi Ghanem A, El Annan T, Ghawi N, Omran N, Natout M, Assi H, et al.
Diagnostics (Basel)
. 2024 Aug;
14(15).
PMID: 39125498
Fibroblast Activation Protein Inhibitor (FAPI) positron emission tomography (PET) imaging has emerged as a useful method for identifying pancreatic disorders, notably pancreatitis. Unlike Fluorine-18 fluorodeoxyglucose (FDG), FAPI uptake is directly...
8.
Saleh Y, Hejleh T, Abdelrahim M, Shamseddine A, Chehade L, Alawabdeh T, et al.
Cancers (Basel)
. 2024 Jun;
16(11).
PMID: 38893200
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths. Classically, liver transplantation (LT) can be curative for HCC tumors within the Milan criteria. Bridging strategies to reduce...
9.
El-Karak F, Shamseddine A, Omar A, Haddad I, Abdelgawad M, Naqqash M, et al.
Ecancermedicalscience
. 2024 May;
18:1695.
PMID: 38774566
Prostate cancer (PC) is the second most prevalent cancer in males, with a steadily increasing incidence in the Middle East (ME). The aim of this study was to capture real-world...
10.
Sbaity E, Tamim H, Fuleihan G, Abbas J, Zahwe M, El Sayed R, et al.
BMC Cancer
. 2024 May;
24(1):560.
PMID: 38704543
Background: Developing countries have a significantly higher incidence of breast cancer in patients younger than 40 years as compared to developed countries. This study aimed to examine if young age...